Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy By Ogkologos - August 25, 2025 567 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a meta-analysis performed by the Early Breast Cancer Trialists’ Collaborative Group Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia November 3, 2021 Bus Driver Finds Out Teen With Cancer Can’t Afford Prom &... June 19, 2019 EMA Recommends Extension of Indications for Daratumumab June 10, 2021 FDA Approves Ivosidenib in Combination with Azacitidine for Newly Diagnosed AML June 13, 2022 Load more HOT NEWS Receiving a Blood Transfusion During Cancer: What to Know and What... Mesothelioma Awareness Day: Spotlight on the PrE0506/DREAM3R Clinical Trial FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for HER2-positive Breast... Nirogacestat May Offer Hope to People with Desmoid Tumors
